Esperion amends Q2 earnings; reports $82.4M revenue, first operating income of $7.1M

Esperion Therapeutics, Inc.

2025-Q2 EPS reported -$0.27 revenue$147,380,000

Net loss narrowed to $12.7M from $61.9M in Q2 2024; EPS loss $0.06 vs $0.33.
U.S. net product revenue rose 42% Y/Y to $40.3M; total revenue grew 12% to $82.4M.
Achieved $7.1M operating income, first quarter of positive operating income from ongoing ops.
Reached ANDA settlements blocking generic bempedoic acid until 2040.
Cash $86.1M at June 30; expects sustainable profitability starting Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.